Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Equillium, Inc. (EQ : NSDQ)

• Company Description    Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $2.50 Daily Weekly Monthly 20 Day Moving Average: 25,257 shares Shares Outstanding: 34.28 (millions) Market Capitalization: $85.69 (millions) Beta: 1.31 52 Week High: $7.75 52 Week Low: $2.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.25% -7.21% 12 Week -37.19% -29.41% Year To Date -33.69% -18.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2223 Avenida de la Playa Suite 105 - LA JOLLA,CA 92037 USA ph: 858-412-5302 fax: - ir@equilliumbio.com http://www.equilliumbio.com

• General Corporate Information    Officers Bruce D. Steel - President and Chief Executive Officer Daniel M. Bradbury - Chairman of the Board of Directors Jason A. Keyes - Chief Financial Officer Stephen Connelly - Director Martha J. Demski - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29446K106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 34.28 Most Recent Split Date: (:1) Beta: 1.31 Market Capitalization: $85.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.63 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -36.36% vs. Previous Quarter: -25.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -63.54 12/31/21 - -48.97 09/30/21 - -46.35 ROA 03/31/22 - -50.49 12/31/21 - -40.62 09/30/21 - -38.85 Current Ratio 03/31/22 - 5.50 12/31/21 - 9.35 09/30/21 - 11.85 Quick Ratio 03/31/22 - 5.50 12/31/21 - 9.35 09/30/21 - 11.85 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.54 12/31/21 - 2.26 09/30/21 - 2.58 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.14 12/31/21 - 0.13 09/30/21 - 0.12 Debt-to-Capital 03/31/22 - 12.28 12/31/21 - 11.63 09/30/21 - 10.48

Powered by Zacks Investment Research ©